PressJuly 29, 2026 SciSparc: Subsidiary NeuroThera Labs Advances its Quantum Platform for Clinical Data Analytics on a Platform of an S&P 500 company
PressJuly 29, 2026 Compass Pathways to Announce Second Quarter and First Half 2026 Financial Results on August 5, 2026
PressJuly 28, 2026 Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia as Chief Business Officer
PressJuly 27, 2026 SciSparc Announces Decision to Target the Agentic AI Market; Forms Scientific Advisory Board for Artificial Intelligence and Cybersecurity
PressJuly 21, 2026 Pasithea Therapeutics Announces Presentation of PAS-004 Data to European Society for Medical Oncology (ESMO) Congress 2026
PressJuly 16, 2026 Eli Lilly to acquire AtaiBeckley for about $2.8 billion, up to $3.8 billion with milestones
PressJuly 16, 2026 Relmada Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026
PressJuly 16, 2026 Definium Therapeutics Launches Wired for Worry, a Health Care Provider Initiative to Advance the Understanding of Generalized Anxiety Disorder (GAD) Patient Impact and Neurobiology
PressJuly 16, 2026 Compass Pathways Announces Publication of Post-Hoc Analysis Demonstrating Distinction of COMP360 Trial Monitoring & Support from Psychotherapy
PressJuly 15, 2026 SciSparc: NeuroThera Labs Announces Initiation of Phase IIb Clinical Trial at Hannover Medical School in Germany for Innovative Treatment of Tourette Syndrome
PressJuly 14, 2026 FDA finalizes psychedelic clinical trial guidance and schedules September public hearing
PressJuly 14, 2026 Silo Pharma's QwikAgents Joins AMD AI Developer Program to Advance Enterprise AI Agent Platform
PressJuly 7, 2026 Compass Pathways reports six-month Phase 3 COMP006 data confirming durable psilocybin response
PressJuly 6, 2026 AtaiBeckley doses last patient in Phase 2b Elumina trial of VLS-01 for treatment-resistant depression
